BioSpace News Archive

Multiplexed Target Enrichment Panel Sequences the Entire Viral Genome for High Coverage of Target Regions, Better Accuracy and Mutation Tracking

Largest study of a nationally representative American population demonstrates cotesting outperforms HPV or Pap testing alone in detecting cancer and precancer in women 30 years and older

Plex Pharmaceuticals, Inc., announced that it has been awarded two Small Business Innovation Research grants from the National Institutes of Health National Eye Institute: a $1.3 million Phase II grant and a $300,000 Phase I grant.

HAPPE Spine announces that it has received notice of allowance from the U.S. Patent and Trademark Office for patent claims providing broad protections for its unique material and manufacturing technology providing fully porous, bioactive polyetheretherketone technology.

Talaris Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug application for the evaluation of Talaris’ novel cell therapy FCR001 in the treatment of diffuse systemic sclerosis, a severe form of the rare autoimmune disease scleroderma.

Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada.

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 138,200 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

Sanofi Canada is pleased to announce that Health Canada has approved SARCLISA™ in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.2

Eikonizo Therapeutics, Inc., a biotechnology company developing novel, first-in-class brain-penetrant HDAC6 inhibitors to slow or stop progression of neurodegenerative disorders, has published results from the First-in-Human Study of [18F]EKZ-001 in healthy volunteers in the European Journal of Nuclear Medicine and Molecular Imaging.

The Grant from the Bill & Melinda Gates Foundation Accelerates Company’s Efforts to Enter Clinical Trials by Early 2021